Abstract
Pretargeted tumour imaging was performed in nude mice bearing subcutaneous LS174T human colon cancer xenografts with streptavidin-CC49 monoclonal antibody and 111In-DTPA-biocytin. Mice were administered 250 micrograms of streptavidin-CC49, followed 6 or 9 days later by 40 ng (250 microCi) of 111In-DTPA-biocytin. Tumors were visualized at 24 h postinjection of 111In-DTPA-biocytin. Tumour uptake was 0.9-2.5% injected dose/g with tumour/nontarget ratios from 2:1 to 37:1 (except for kidney, which was 0.5-3:1). Tumour uptake in mice pretargeted with streptavidin or streptavidin-conjugated nonspecific normal mouse IgG was < 0.1% i.d./g.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal* / pharmacokinetics
-
Antigens, Neoplasm / immunology
-
Antigens, Neoplasm / metabolism
-
Bacterial Proteins* / pharmacokinetics
-
Colonic Neoplasms / diagnostic imaging*
-
Colonic Neoplasms / metabolism
-
Female
-
Glycoproteins / immunology
-
Glycoproteins / metabolism
-
Humans
-
Immunoconjugates* / pharmacokinetics
-
Indium Radioisotopes* / pharmacokinetics
-
Lysine / analogs & derivatives*
-
Lysine / pharmacokinetics
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Pentetic Acid / analogs & derivatives*
-
Pentetic Acid / pharmacokinetics
-
Radionuclide Imaging
-
Streptavidin
-
Tissue Distribution
-
Transplantation, Heterologous
Substances
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Bacterial Proteins
-
Glycoproteins
-
Immunoconjugates
-
Indium Radioisotopes
-
alpha,omega-(bis)DTPA-biocytin
-
tumor-associated antigen 72
-
Pentetic Acid
-
Streptavidin
-
Lysine